title: When should a provider consider insulin human inhalation powder?
abstract: Insulin human inhalation powder, a rapid-acting inhaled insulin, was approved by the FDA in June 2014 for patients with type 1 or type 2 diabetes. For patients reluctant to start insulin therapy because of fear of injections, insulin human inhalation powder may be an alternative. This article discusses appropriate dosing, use, and monitoring.
authors.affiliation: Cortney Mospan is an assistant professor of pharmacy practice at East Tennessee State University's Bill Gatton College of Pharmacy in Johnson City, Tenn. She also serves as a clinical pharmacist with Mooney's Discount Pharmacy. Chelsea Leonard is a community pharmacy resident at Samford University's McWhorter School of Pharmacy in Birmingham, Ala., and Kelli Alley is a community pharmacist with Target in Greensboro, N.C.; both were doctoral candidates in the Bill Gatton College of Pharmacy when this article was written. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Cortney M
authors.initials: CM
authors.lastname: Mospan
authors.forename: Chelsea
authors.initials: C
authors.lastname: Leonard
authors.forename: Kelli
authors.initials: K
authors.lastname: Alley
mesh_terms: D000280:Administration, Inhalation; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D061386:Insulin, Regular, Human
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D061386:Insulin, Regular, Human